Education
About Us
Working with TipRanks
Follow Us
Uniphar PLC (GB:UPR)
:UPR
UPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range163.00p - 240.00p
Previous CloseN/A
Volume3.00K
Average Volume (3M)31.32K
Market Cap
£620.64M
Enterprise Value881.79M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)182.54M
Price to Earnings (P/E)11.6
Beta0.88
Next Earnings
Sep 03, 2025EPS Estimate
7.63Next Dividend Ex-Date
Apr 24, 2025Dividend Yield0.69%
Share Statistics
EPS (TTM)0.20
Shares Outstanding259,574,300
10 Day Avg. Volume31,089
30 Day Avg. Volume31,324
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)N/A
Price to Sales (P/S)22.67
Price to Cash Flow (P/CF)-2022.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
399.93pPrice Target Upside73.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Uniphar PLC News
PremiumCompany Announcements
Uniphar PLC’s Share Buyback Alters Voting Rights StructurePremiumCompany Announcements
Uniphar PLC Announces 2025 AGM and Annual Report Publication
PremiumCompany Announcements
Uniphar PLC Executes Share Buyback to Optimize Capital Structure
PremiumCompany Announcements
Uniphar PLC Announces Change in Voting Rights
PremiumCompany Announcements
Allianz Global Investors Acquires 13.34% Stake in Uniphar PLCPremiumCompany Announcements
Uniphar PLC Executes Share Buyback on Euronext Dublin
PremiumCompany Announcements
Uniphar PLC Executes Strategic Share Buyback---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceUniphar achieved a significant 9.6% growth in group gross profit, reaching €427.6m, with all divisions meeting their organic GP targets for FY24.
New ContractsPharma Services secured 17 new EAP contracts, marking one of its best years for new contracts and expanding its client base to include 10 of the top 20 big pharma companies.
Bears Say
Debt LevelsNet debt is modeled at approximately €250m, raising concerns until the successful execution of the planned sale/leaseback of Uniphar's existing assets.
Valuation ConcernsUniphar shares are trading at unwarranted five-year low multiples, around 9x PE and 5.6x EBITDA for 2025, despite a strong track record since IPO and promising growth prospects.
---
Options Prices
Currently, No data available
---
Ownership Overview
5.22% Insiders
1.00%
Mutual Funds
― Other Institutional Investors
91.75% Public Companies and
Individual Investors
UPR FAQ
What was Uniphar PLC’s price range in the past 12 months?
Uniphar PLC lowest share price was 163.00p and its highest was 240.00p in the past 12 months.
What is Uniphar PLC’s market cap?
Uniphar PLC’s market cap is £620.64M.
When is Uniphar PLC’s upcoming earnings report date?
Uniphar PLC’s upcoming earnings report date is Sep 03, 2025 which is in 137 days.
How were Uniphar PLC’s earnings last quarter?
Uniphar PLC released its earnings results on Feb 25, 2025. The company reported 0.153p earnings per share for the quarter, beating the consensus estimate of 0.11p by 0.044p.
Is Uniphar PLC overvalued?
According to Wall Street analysts Uniphar PLC’s price is currently Undervalued.
Does Uniphar PLC pay dividends?
Uniphar PLC pays a Annually dividend of 1.032p which represents an annual dividend yield of 0.69%. See more information on Uniphar PLC dividends here
What is Uniphar PLC’s EPS estimate?
Uniphar PLC’s EPS estimate is 7.63.
How many shares outstanding does Uniphar PLC have?
Uniphar PLC has 259,574,300 shares outstanding.
What happened to Uniphar PLC’s price movement after its last earnings report?
Uniphar PLC reported an EPS of 0.153p in its last earnings report, beating expectations of 0.11p. Following the earnings report the stock price went up 7.463%.
Which hedge fund is a major shareholder of Uniphar PLC?
Currently, no hedge funds are holding shares in GB:UPR
---
Company Description
Uniphar PLC
Uniphar plc operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, and internationally. The company operates through three divisions: Commercial & Clinical, Product Access, and Supply Chain & Retail. The Commercial & Clinical division offers outsourced sales, marketing, and multichannel account management services to pharmaco-medical manufacturers; and distribution and support services to medical device manufacturers. The Product Access division provides on demand services, which provides access to pharmaco-medical products and treatments by developing valuable relationships and interactions between manufacturers and other healthcare stakeholders; and exclusive access services that offers bespoke distribution partnerships to pharmaceutical partners for key brands. The Supply Chain & Retail division engages in pre-wholesale and wholesale distribution of pharmaceutical, healthcare, and animal health products to pharmacies, hospitals, and veterinary surgeons; and operates a network of pharmacies under the Life, Allcare, and Hickey's brands. It also offers pharmacy support, pharmaceutical supply chain, specialist nursing and infusion, medical device distribution, healthcare technology, data intelligence and consultancy services, pharmaceutical advisory, medical affairs, and online pharmacy and product fostering services, as well as data solutions for pharma industry. Uniphar plc was founded in 1967 and is headquartered in Dublin, Ireland.
---
UPR Stock 12 Month Forecast
Average Price Target
399.93p
▲(73.88% Upside)
Technical Analysis
EKF Diagnostics Holdings
―
Hikma Pharmaceuticals
―
PureTech Health
―
Tissue Regenix
―
Best Analysts Covering UPR
1 Year
1 Year Success Rate
5/5 ratings generated profit
1 Year Average Return
+9.54%
reiterated a buy rating 29 days ago
Copying Christian Glennie's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +9.54% per trade.
---